Notice

Life Sciences Innovative Manufacturing Fund (LSIMF): Phase 2 (closed to applications)

This fund is to support businesses investing in life sciences manufacturing projects in the UK.

Documents

Grant offer letter: draft template

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alt.formats@dsit.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

As part of the £4.5 billion funding for strategic manufacturing sectors at the Autumn Statement 2023, we have made available £520 million funding for life sciences manufacturing over five years (2025-2030).

This funding will build resilience for future health emergencies and capitalise on the UK’s world-leading research and development capabilities. An announcement will be made via our Office for Life Sciences newsletter. If you would like to be added to the copy list, please email Futurecapitalfund@officeforlifesciences.gov.uk.

The Life Sciences Innovative Manufacturing Fund (LSIMF) Phase 2 is now closed to new applications.

Background and objectives of the programme

The Life Sciences Innovative Manufacturing Fund (LSIMF) is part of the Global Britain Investment Fund and will provide £60 million in capital grants for investment in the manufacture of:

  • human medicines (drug substance and drug product)
  • medical diagnostics
  • MedTech products

We have already announced the first tranche of companies to be supported by LSIMF and are now re-opening the fund with the remaining budget of £7.6 million.

Specific themes

We particularly welcome applications from companies with manufacturing investments that demonstrate the adoption of innovative process technologies, for example:

  • flexible manufacturing enabling rapid product switching
  • continuous manufacturing
  • technologies that will minimise impact of the product or the manufacturing process on the environment
  • digital twins, which harness the power of data analytics and modelling to optimise manufacturing processes

This list is not exhaustive.

Fund objectives

We will prioritise applicants based on their alignment to the fund’s objectives:

1. Creating economic opportunity through investments that will provide high-wage, high-skilled jobs.

2. Deploying cutting-edge innovations (at both pilot and commercial scale) which can be embedded in either the product itself or the manufacturing process.

3. Increasing health resilience, either through increased domestic capacity or by providing flexible capabilities that can be re-deployed in some way in a future health emergency.

4. Minimising impact on the environment, which might include reduction in input resources or using alternative input materials to become more sustainable or support the government’s net zero target.

Contact

Contact the LSIMF support team if you have any queries about the fund: LSIMF@officeforlifesciences.gov.uk.

Published 2 March 2022
Last updated 26 February 2024 + show all updates
  1. Life Sciences Innovative Manufacturing Fund (LSIMF): Phase 2 closed to applications.

  2. Phase 2 open to Expressions of Interest.

  3. Phase 1 is now closed to Expressions of Interest.

  4. Submit expressions of interest for Phase 1, Wave 3 by 31 May 2022, 12 noon.

  5. Wave 2 expressions of interest date added.

  6. Date for submitting expressions of interest to the LSIMF Phase 1 Wave 1 changed to Friday 29 April at 12 noon.

  7. First published.